Alzheimer's articles
Scientific articles published by the researchers of Barcelonaβeta Brain Research Center (BBRC), related to Alzheimer's disease, neuroimaging, memory and neurodegenerative diseases, among other fields.
-
Gallay C, Soldevila-Domenech N, López-Martos D, Sanchez-Benávides G, Huguet J, Suárez-Calvet M, Gispert JD, Salvadó G, Sundermann EE, Grau-Rivera O, Brugulat-Serrat A; for ALFA study.
Effect of Parity and β-Amyloid on Cognition and Hippocampal Volume in Postmenopausal Women
NeurologyAbstractBackground and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD...
-
López-Martos D, Suárez-Calvet M, Salvadó G, Cacciaglia R, Shekari M, González-Escalante A, Horta-Barba A, Palma-Gudiel H, Milà-Alomà M, Brugulat-Serrat A, Minguillon C, Tonietto M, Borroni E, Klein G, Quijano-Rubio C, Kollmorgen G, Zetterberg H, Blennow K, Gispert JD, Sánchez-Benavides G, Grau-Rivera O; ALFA study.
Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals
Neurobiology of AgingAbstractAlzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is...
-
Contador J, Pozzi FE, Sánchez-Benavides G, Fernández-Arcos A, Lantero-Rodríguez J, Montoliu-Gaya L, Minguillon C, Fauria K, González-Escalante A, Ortiz-Romero P, Blasco-Forniés H, de Diego-Osaba M, Jiménez Moyano E, Quijano-Rubio C, Kollmorgen G, Le Bastard N, Nadal A, Vanmechelen E, Jeromin A, Torres-Torronteras J, Ashton NJ, Zetterberg H, Blennow K, Gispert JD, Molinuevo JL, Del Campo M, Grau-Rivera O, Suárez-Calvet M; β-AARC Study collaborators.
Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers
EBioMedicineAbstractBackground: Subjective cognitive decline (SCD) may represent an early stage of Alzheimer's disease (AD), but biomarker studies in this population are limited. Therefore, we compared the performance of...
-
Serrano-Pozo A, Escott-Price V, Grinberg LT, Pascoal T, Suárez-Calvet M, Dubois B, Sperling RA.
Alzheimer's disease
LancetAbstractAlzheimer's disease is the leading cause of dementia and among the top ten leading causes of death in high-income countries. Exponential advances in epidemiology, genetics, diagnostic imaging and...
-
Suárez-Calvet M, Salvadó G, de Fortuny BB, Del Campo M.
Blood biomarkers for Alzheimer's disease: from detection to decisions
Lancet -
Fernández-Lebrero A, Jiménez-Balado J, García-Escobar G, Contador J, Estraguès-Gázquez I, Peraferrer-Montesinos L, Suárez-Pérez A, Manero-Borràs RM, Beltrán B, Gramegna L, Campello AR, Palacio-Gili A, Grau O, Suárez-Calvet M, Ois A, Puig-Pijoan A, Navalpotro-Gómez I.
CSF Biomarker Profile of Cerebral Amyloid Angiopathy: Diagnostic Performance and Imaging Correlates in a Hospital-Based Neurology Cohort
European Journal of NeurologyAbstractBackground: Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer's disease (AD), complicating diagnosis in patients with cognitive impairment. The CSF biomarker profile of CAA remains...
-
Toccaceli Blasi M, Salzillo M, Buscarnera S, Nuti F, Stanziale C, Pecorari C, Ottone DA, Salati E, D'Antonio F, Canevelli M, Bruno G.
A diary-based approach to improve neuropsychiatric symptom assessment in dementia: A cross-sectional comparison with the neuropsychiatric inventory
Journal of Alzheimer's DiseaseAbstractBackgroundNeuropsychiatric symptoms (NPS) are among the most challenging manifestations of dementia. Currently available assessment tools often fail to fully capture their complexity. Thus, novel...
-
Shekari M, Escalante AG, Milà-Alomà M, Falcon C, López-Martos D, Sánchez-Benavides G, Brugulat-Serrat A, Niñerola-Baizán A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Montoliu-Gaya L, Snellman A, Day TA, Dage JL, Ortiz-Romero P, Tonietto M, Borroni E, Klein G, Kollmorgen G, Carboni M, Quijano-Rubio C, Vanmechelen E, Minguillón C, Fauria K, Perissinotti A, Molinuevo JL, Zetterberg H, Blennow K, Grau-Rivera O, Suárez-Calvet M, Gispert JD; ALFA Study.
Associations of 18F-RO-948 tau PET with fluid AD biomarkers, Centiloid, and cognition in early AD continuum
Alzheimer's & DementiaAbstractIntroduction: We examined neurofibrillary tangle (NFT) pathology using 18F-RO-948 tau positron emission tomography (PET) in cognitively unimpaired individuals and its associations with amyloid plaques...
-
Hortsch S, Domenico AD, Borlinghaus N, Caley D, Kaminioti-Dumont L, Jeppesen SB, González-Escalante A, Ritchie C, Frederiksen KS, Suárez-Calvet M.
Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice
The journal of prevention of Alzheimer's DiseaseAbstractBackground: With the emergence of disease-modifying anti-amyloid-beta (Aβ) therapies for Alzheimer's disease (AD), early and accurate quantitative measures of Aβ burden are critical. Blood-based...
-
Reiman EM, Alexander RC, Langbaum JB, Aisen PS, Ashton N, Atri A, Barbarino P, Byrd GS, Feldman HH, Fowler NR, Ghisays V, Grill JD, Hassenstab J, Heaton GR, Herring WL, Jack CR Jr, Johnson SC, Karlawish J, Keach NL, Kivipelto M, Krumholz HM, Largent EA, MaGee-Rodgers T, McDade E, Mielke MM, Molina-Henry D, Petersen RC, Rabinovici GD, Ritchie C, Schindler SE, Sperling RA, Suárez-Calvet M, Vradenburg G, Weiner MW, Welsh-Bohmer KA, Zetterberg H, Zuendel MT, Mattke S, Cummings JL
A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
The Lancet NeurologyAbstractAntibody therapies can remove amyloid plaques from the brain and slow cognitive decline in people with Alzheimer's disease who are mildly impaired. These drugs are now being evaluated in participants...
